Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G, Brixner D, Biskupiak J, Burgoyne D, Arondekar B, Deal LS, Quek RG, Niyazov A. Oderda G, et al. Among authors: niyazov a. J Manag Care Spec Pharm. 2022 Feb;28(2):188-195. doi: 10.18553/jmcp.2021.21223. Epub 2021 Nov 22. J Manag Care Spec Pharm. 2022. PMID: 34806908
Almost half (47.1%) suggested formulary review would be influenced by a lack of PRO evidence from oncology clinical trials either somewhat, much, or a great deal. ...Biskupiak, Oderda, and Brixner are managers of Millcreek Outcomes Group and were paid as consultants …
Almost half (47.1%) suggested formulary review would be influenced by a lack of PRO evidence from oncology clinical trials either som …
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP. Mahtani R, et al. Among authors: niyazov a. Adv Ther. 2023 Jan;40(1):331-348. doi: 10.1007/s12325-022-02302-2. Epub 2022 Oct 28. Adv Ther. 2023. PMID: 36333567 Free PMC article.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: niyazov a. Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. Breast. 2022. PMID: 36368161 Free PMC article.
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: niyazov a. BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. BMC Cancer. 2022. PMID: 36550413 Free PMC article.
Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries.
Lux MP, Lewis K, Rider A, Niyazov A. Lux MP, et al. Among authors: niyazov a. Breast Care (Basel). 2022 Oct;17(5):460-469. doi: 10.1159/000523970. Epub 2022 Mar 11. Breast Care (Basel). 2022. PMID: 36684399 Free PMC article.
Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D, Biskupiak J, Oderda G, Burgoyne D, Malone DC, Arondekar B, Niyazov A. Brixner D, et al. Among authors: niyazov a. J Manag Care Spec Pharm. 2021 Aug;27(8):1096-1105. doi: 10.18553/jmcp.2021.27.8.1096. J Manag Care Spec Pharm. 2021. PMID: 34337998 Free PMC article.
Differences in responses for categorical data were compared using a Pearson Chi-Square or a Fisher's Exact test. Two-tailed values are reported and a level of 0.05 was used to indicate statistical significance. ...Burgoyne was a consultant for Pfizer o …
Differences in responses for categorical data were compared using a Pearson Chi-Square or a Fisher's Exact test. Two-tailed va …
30 results